JUUL LABS CHIEF REGULATORY OFFICER, JOE MURILLO, DETAILS MONOGRAPH PUBLICATION IN FOOD & DRUG LAW INSTITUTE NEWSLETTER
April 27, 2021
As part of Juul Labs’ continued commitment to reset the category and company by earning trust, we remain focused on advancing a science and evidence-based dialogue with regulators, policymakers, public health leaders, and other stakeholders.
In April 2021, we announced a significant milestone in our efforts to contribute to this dialogue with the publication of 11 peer-reviewed studies in a monograph edition of the American Journal of Health Behavior (AJHB). The articles published in the AJHB represent a significant portion of our research portfolio and our Premarket Tobacco Product Application (PMTA) in the U.S., including our core behavioural data.
Coinciding with the monograph publication, Juul Labs’ Chief Regulatory Officer, Joe Murillo, published a piece entitled “Juul Labs: Advancing the Scientific Dialogue About Tobacco Harm Reduction” in the Food & Drug Law Institute (FDLI) newsletter. In addition to discussing key findings from the monograph publication, the piece details the importance of FDA’s oversight role of the category and the science- and evidence-based PMTA process. He also discusses the company’s commitment to fostering much-needed scientific dialogue about the harm reduction potential of ENDS products by engaging with the public health community on the science and facts underlying our products.
Excerpts from the FDLI Newsletter
- Determining the public health impact of alternative noncombustible tobacco products, and providing a process for their marketing authorisation, is a key tenet of the agency’s 2017 Comprehensive Plan for Tobacco and Nicotine Regulation. Under the Comprehensive Plan, FDA seeks to implement science-based regulations that will help smokers who would not otherwise quit move down the continuum of risk to less harmful noncombustible nicotine alternatives. The Comprehensive Plan is firmly rooted in the concept of tobacco harm reduction—and nicotine is its centrepiece.
- As a company, we are committed to working collaboratively with regulators, policymakers, public health leaders, and other stakeholders as we strive to earn a license to operate in society. We understand that in order to foster this much-needed scientific dialogue about the harm reduction potential of ENDS products, including JUUL, we must engage with the public health community on the science and facts underlying our products. In furtherance of this goal, we have published five articles and presented over 45 posters at various scientific and policy conferences around the world.
- This month we celebrate a significant milestone in those efforts with the publication of 11 articles in a monograph edition of the American Journal of Health Behavior (AJHB). The monograph focuses on the centrepiece of our behavioural research program: the Adult Juul User Switching and Smoking Trajectories (ADJUSST) study. The ADJUSST study sought to understand patterns of tobacco product use among adult JUUL product purchasers, and collected data on over 55,000 current, former, and never smokers over the course of a year. The ADJUSST study found high switching rates—defined as no past-30 day smoking, not even a puff—of over 50% across established smokers.
- The research also examined patterns of tobacco use across populations of special interest, including smokers of different ethnic groups, income levels, and mental health comorbidities. Encouragingly, results from the ADJUSST study demonstrate very similar high switching patterns among these cohorts compared to the general population.
- In addition to adult behavioural data, the monograph also includes an article assessing the potential effectiveness of enhanced access controls implemented at retail stores selling JUUL products. Juul Labs firmly believes the harm reduction potential of ENDS for adult smokers is at risk with high levels of underage use.
- Finally, the monograph closes with an article detailing the population health model submitted to FDA, taking into account both intended and unintended use of our products. Relying on data from ADJUSST and other sources (PATH, NYTS, Royal College of Physicians, etc.), the model projects that continued availability of ENDS like JUUL could prevent up to 2.5 million premature deaths by the year 2100.
